S (+) -flurbiprofen axetil emulsion for injection

A technology of flurbiprofen axetil and flurbiprofen, applied in the field of S(+)-flurbiprofen axetil injection emulsion, which can solve problems such as increased gastrointestinal side effects and lack of cyclooxygenase inhibitory activity

Inactive Publication Date: 2013-09-18
FUKANGREN BIO PHARMA
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The current clinical application is its racemate. Studies have found that the active source of flurbiprofen axetil is mainly its S(+)-enantiomer, while the R(-)-enantiomer lacks significant cyclooxygenase Inhibiting activity, t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • S (+) -flurbiprofen axetil emulsion for injection
  • S (+) -flurbiprofen axetil emulsion for injection
  • S (+) -flurbiprofen axetil emulsion for injection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Preparation of S(+)-flurbiprofen axetil injection emulsion

[0016] Preheat 50g of soybean oil for injection to 60 degrees Celsius, add 5g of S(+)-flurbiprofen axetil, dissolve, and then disperse 6g of egg yolk lecithin in it to obtain an oil phase; mix 11.25g of glycerin for injection and 0.25g Add disodium hydrogen phosphate to water for injection, and preheat to 60 degrees Celsius to obtain the water phase; disperse the oil phase in the water phase, stir at 8000rpm for 20 minutes to make rough milk; homogenize the thick milk under 700bar high pressure for 6 times, Obtain essence milk; adjust the pH of essence milk to 6.5 with citric acid, filter through a 0.8 micron filter membrane, fill in 5ml ampoules, and sterilize at 121 degrees Celsius for 15 minutes to obtain the finished product. The specification of the obtained emulsion for injection is 50mg / 5ml.

[0017] The following pharmacological studies were carried out using the emulsion for injection prepared in the...

Embodiment 2

[0019] Analgesic effect of S(+)-flurbiprofen axetil injection milk

[0020] 30 KM mice, half male and half female, weighing 18-22 g, were randomly divided into 3 groups, 10 mice in each group. They are model control, flurbiprofen axetil injection group, and S(+)-flurbiprofen axetil injection milk group (please refer to the declared patent 201210153560.1 for the preparation prescription and process). All groups were administered by injection. After 10 minutes of administration, each mouse was intraperitoneally injected with 0.6% acetic acid solution 0.1mL / 10g. Observe the number of writhing reactions in mice within 15 minutes, calculate the analgesic inhibition rate, and compare between groups. The results showed that, compared with the control group, each treatment group had obvious analgesic effect, and the effect of S(+)-flurbiprofen axetil injection milk group was more significant. see table 1

[0021] Table 1 Inhibitory effect of drugs on acetic acid writhing response i...

Embodiment 3

[0025] Pharmacokinetics of S(+)-flurbiprofen axetil injection milk

[0026] Based on the findings in Example 1, the pain intensity of S(+)-flurbiprofen axetil injection emulsion is about 1.4 times that of flurbiprofen axetil injection. In other words, it is expected that a smaller dose of S(+)-flurbiprofen axetil injection emulsion can achieve the same pain effect as flurbiprofen axetil injection. Therefore, in the follow-up study, the dose of S(+)-flurbiprofen axetil injection emulsion was reduced to 50% and 75% of the above study.

[0027] 40 KM mice, half male and half female, weighing 18-22 g, were randomly divided into 4 groups, 10 mice in each group. Each group was administered by injection, and the doses were 0 (vehicle), 10 mg / kg (flurbiprofen axetil injection), 5 and 7.5 mg / kg (S(+)-flurbiprofen axetil injection emulsion), and After 10 minutes of drug administration, each mouse was intraperitoneally injected with 0.6% acetic acid solution 0.1 mL / 10 g. Observe the n...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a low-dosage esflurbiprofen axetil emulsion for injection. For the S (+) -flurbiprofen axetil emulsion for injection provided by the invention, when a certain curative effect is realized, the needed dosage of the S (+) -flurbiprofen axetil emulsion for injection is only 25%-75% of the dosage of the market flurbiprofen axetil emulsion, correspondingly, the clinic treatment dosage of the S (+) -flurbiprofen axetil emulsion for injection is 25%-75% of the market flurbiprofen axetil emulsion.

Description

technical field [0001] The invention relates to an S(+)-flurbiprofen axetil injection emulsion, which belongs to the technical field of medicine. Background technique [0002] Flurbiprofen axetil is a prodrug of flurbiprofen. Pain relief after surgery and various cancers. Flurbiprofen axetil injection is a non-steroidal targeted analgesic, which reduces the synthesis of prostaglandins by inhibiting cyclooxygenase (COX) in the spinal cord and peripheral, and reduces the hyperalgesia state caused by surgical trauma. [0003] The chemical structure of flurbiprofen axetil is as follows: [0004] [0005] The current clinical application is its racemate. Studies have found that the active source of flurbiprofen axetil is mainly its S(+)-enantiomer, while the R(-)-enantiomer lacks significant cyclooxygenase Inhibiting activity, the gastrointestinal toxicity of this racemate is increased due to the presence of the R(-)-enantiomer. Therefore, from a theoretical point of view,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/107A61K31/216A61P29/00
Inventor 不公告发明人
Owner FUKANGREN BIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap